Kaigene, Taisho Advance KG006 Autoimmune Therapy Deal
ROCKVILLE, Md. and TOKYO, July 30, 2026 Kaigene has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co.,...
Celltrion
Advertisement
FDA Grants Interchangeability for Celltrion’s Denosumab Biosimilars
Incheon, South Korea, October 30, 2025 — Celltrion, Inc., a global biopharmaceutical company specializing in biosimilars and innovative biologics,...
Celltrion Gains FDA Nod for YUFLYMA Pediatric Use Expansion
Incheon, South Korea – October 16, 2025 – CelltrionUSA, a subsidiary of Celltrion Inc., announced that the U.S. Food...
Celltrion Secures FDA Approval for EYDENZELT® in Multiple Retinal Diseases
INCHEON, South Korea, Oct. 9, 2025 — Celltrion, Inc., a global biopharmaceutical innovator, announced that the U.S. Food and...
Advertisement
